Performance monitoring of regional citrate anticoagulation

Patent metadata

Field	Value
Publication number	US-2022016325-A1
Application number	US-201917311874-A
Country	US
Kind code	A1
Filing date	Oct 30, 2019
Priority date	Dec 11, 2018
Publication date	Jan 20, 2022
Grant date	—

Abstract

A monitoring device operates to monitor regional citrate anticoagulation (RCA) in a blood treatment system which is configured to administrate citrate to an extracorporeal blood circuit (10) upstream of a dialyzer (11) during a treatment session. At consecutive time steps during the treatment session, the monitoring device obtains a current measurement value of systemic ionized calcium (iCaSYS) or systemic total calcium (CaSYS), operates a predefined algorithm on the current measurement value to generate a current computation value that represents ionized calcium (iCa2, iCa3) in blood at a selected location (loc2, loc3) downstream or upstream of the dialyzer (11) in the extracorporeal blood circuit (10), and presents and/or evaluates the current computation value for assessment of the regional citrate anticoagulation. The need for conventional blood sampling and blood analysis upstream and/or downstream of the dialyzer, e.g. during CRRT, is thereby reduced significantly.

First claim

1 - 27 . (canceled)

28 : A monitoring device for a blood treatment system, the blood treatment system comprising an extracorporeal blood circuit which comprises a blood withdrawal line and a blood return line for connection to a vascular system of a subject and a dialyzer intermediate the blood withdrawal and blood return lines, wherein the blood treatment system is configured for regional citrate anticoagulation by administration of citrate to the extracorporeal blood circuit upstream of the dialyzer during a treatment session, said monitoring device comprising:
a memory; and a processor in communication with the memory, the processor configured to, at consecutive time steps during the treatment session:
obtain a current measurement value of systemic ionized calcium or systemic total calcium,
operate a predefined algorithm on the current measurement value to generate a current computation value that represents ionized calcium in blood at a selected location downstream or upstream of the dialyzer in the extracorporeal blood circuit, and
display, via a display device, the current computation value, and/or determine an assessment of the regional citrate anticoagulation based on the current computation value.

29 : The monitoring device of claim 28 , wherein the processor is further configured to obtain input data comprising current values of operation parameters of the blood treatment system, and optionally one or more of system configuration data for the blood treatment system, chemical parameter data for substances in the blood, and physiological parameter data for the subject, wherein the processor is configured to operate the predefined algorithm on the input data and the current measurement value to generate the current computation value.

30 : The monitoring device of claim 28 , wherein the predefined algorithm comprises a first function configured to estimate the ionized calcium in the blood at the selected location in the extracorporeal blood circuit, said first function being linearly dependent on total calcium at the selected location and total citrate at the selected location.

31 : The monitoring device of claim 30 , wherein the first function is obtained by linearization of a non-linear function with respect to each of total calcium and total citrate, wherein the non-linear function is a solution to a system of equations representing chemical reactions of calcium in free form and bound to other substances in blood, including citrate, while assuming predefined amounts of other substances than calcium and citrate.

32 : The monitoring device of claim 31 , wherein the linearization is performed with respect to reference values of total calcium and total citrate, said reference values corresponding to expected values of total calcium and total citrate, respectively, at the selected location.

33 : The monitoring device of claim 30 , wherein the predefined algorithm comprises a second function configured to estimate the total calcium in the blood at the selected location.

34 : The monitoring device of claim 33 , wherein the selected location is downstream of the dialyzer, and wherein the second function depends on the systemic total calcium and represents a mass balance of total calcium that enters the extracorporeal blood circuit in the blood from the subject and total calcium in the blood at an intermediate location in the extracorporeal blood circuit upstream of the dialyzer, while accounting for fluid infusion into the extracorporeal blood circuit intermediate the subject and the intermediate location, wherein the second function further accounts for a loss of total calcium from the blood in the dialyzer.

35 : The monitoring device of claim 30 , wherein the predefined algorithm comprises a third function configured to estimate the total citrate in the blood at the selected location in the extracorporeal blood circuit.

36 : The monitoring device of claim 35 , wherein the selected location is downstream of the dialyzer, wherein the third function depends on systemic total citrate and represents a mass balance of total citrate that enters the extracorporeal blood circuit in the blood from the subject and total citrate at an intermediate location in the extracorporeal blood circuit upstream of the dialyzer, while accounting for fluid infusion into the extracorporeal blood circuit intermediate the subject and the intermediate location, wherein the third function further accounts for a loss of total citrate from the blood in the dialyzer.

37 : The monitoring device of claim 30 , wherein the predefined algorithm further comprises a fourth function configured to estimate systemic total citrate as a function of time from start of the regional citrate anticoagulation.

38 : The monitoring device of claim 37 , wherein the fourth function represents a metabolic generation rate of citrate in the subject and further accounts for the administration of citrate into the extracorporeal blood circuit upstream of the dialyzer and a loss of total citrate from the blood in the dialyzer.

39 : The monitoring device of claim 30 , wherein the predefined algorithm further comprises at least one fifth function configured to estimate a clearance of total citrate and a clearance of total calcium from the blood in the dialyzer, wherein the processor is configured to compute a loss of total citrate and a loss of total calcium in the dialyzer based on the clearance of total citrate and the clearance of total calcium, respectively.

40 : The monitoring device of claim 30 , wherein the predefined algorithm comprises a sixth function configured to estimate systemic total calcium as a function of the systemic ionized calcium.

41 : The monitoring device of claim 30 , wherein the predefined algorithm comprises a seventh function configured to estimate the systemic ionized calcium as a function of the systemic total calcium.

42 : The monitoring device of claim 28 , wherein the current measurement value represents the systemic ionized calcium in the blood of the subject, wherein the processor is further configured to operate the predefined algorithm on the current measurement value to generate a further current computation value representing the systemic total calcium.

43 : The monitoring device of claim 28 , wherein the current measurement value represents the systemic total calcium, wherein the processor is further configured to operate the predefined algorithm on the current measurement value to generate a further current computation value representing the systemic ionized calcium.

44 : The monitoring device of claim 28 , wherein the processor is further configured to operate the predefined algorithm to generate a further current computation value representing systemic total citrate.

45 : The monitoring device of claim 42 , wherein the processor is further configured to evaluate at least the further current computation value for assessment of accumulation of citrate in the subject.

46 : The monitoring device of claim 28 , which further comprises an interface configured for signal communication with a blood analysis apparatus, wherein the processor is further configured to, at the respective consecutive time step, obtain the measurement value from a signal received over the interface from the blood analysis apparatus.

47 : The monitoring device of claim 28 , which is further configured to output the current computation value for presentation on a display device.

48 : The monitoring device of claim 2

Assignees

• Gambro Lundia Ab

Inventors

• Hobro Sture
• Alson Jonas
• Nilsson Anders
• Forsal Innas

Classifications

• A61M2205/3334

  Measuring or controlling the flow rate · CPC title

• A61M2230/20

  Blood composition characteristics · CPC title

• A61M2205/3327

  Measuring · CPC title

• A61M1/3437

  downstream of the filter, e.g. post-dilution with filtrate · CPC title

• A61M1/3434 Primary

  with pre-dilution and post-dilution · CPC title